Abstracts tagged "ANCA"

Abstract Number: 2735 • 2018 ACR/ARHP Annual Meeting
Identifying ANCA-Associated Vasculitis Cases in Electronic Health Records Using Natural Language Processing
Zachary Wallace¹, John H. Stone² and Hyon K. Choi³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Epidemiologic studies of ANCA-associated vasculitis (AAV) using large data sets are often limited by the lack of validated definitions of AAV cases that can…
Abstract Number: 1746 • 2018 ACR/ARHP Annual Meeting
Impact of Interstitial Lung Disease on the Long-Term Survival in 76 Japanese Patients with Microscopic Polyangiitis
Hiromi Matsushita¹, Yoshioki Yamasaki², Yukiko Takakuwa³, Hidehiro Yamada⁴ and Kimito Kawahata³, ¹Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan
Background/Purpose: ANCA-associated vasculitis including microscopic polyangiitis (MPA) involves multiple organs including lungs. Clinical characteristics and impact on long-term survival in MPA patients with interstitial lung disease (ILD) have not…
Abstract Number: 1965 • 2018 ACR/ARHP Annual Meeting
Association of HLA Class II Alleles with Relapse and Interstitial Lung Disease in Myeloperoxidsae (MPO) -ANCA Positive Vasculitis in a Japanese Population
Aya Kawasaki¹, Ken-ei Sada², Fumio Hirano^3,4, Shigeto Kobayashi⁵, Hidehiro Yamada⁶, Hiroshi Furukawa^1,7, Kenji Nagasaka⁸, Takahiko Sugihara⁹, Kunihiro Yamagata¹⁰, Takayuki Sumida¹¹, Shigeto Tohma^12,13, Shoichi Ozaki⁶, Hiroshi Hashimoto¹⁴, Hirofumi Makino¹⁵, Yoshihiro Arimura¹⁶, Masayoshi Harigai¹⁷ and Naoyuki Tsuchiya¹, ¹University of Tsukuba, Faculty of Medicine, Molecular and Genetic Epidemiology Laboratory, Tsukuba, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁴Tokyo Medical and Dental UniversityGraduate School of Medical and Dental Sciences, Department of Lifetime Clinical Immunology, Tokyo, Japan, ⁵Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁶St. Marianna University, School of Medicine, Department of Internal Medicine, Kawasaki, Japan, ⁷National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Sagamihara, Japan, ⁸Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ⁹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁰University of Tsukuba, Faculty of Medicine, Department of Nephrology, Tsukuba, Japan, ¹¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹²National Hospital Organization Tokyo Hospital, Sagamihara, Japan, ¹³National Hospital Organization Tokyo National Hospital, Kiyose, Japan, ¹⁴Juntendo University School of Medicine, Tokyo, Japan, ¹⁵Okayama University Hospital, Okayama, Japan, ¹⁶Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ¹⁷Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: The high prevalence of microscopic polyangiitis (MPA) and myeloperoxidase (MPO)-ANCA positive patients as well as frequent occurrence of interstitial lung disease (ILD) constitute unique…
Abstract Number: 2737 • 2018 ACR/ARHP Annual Meeting
Opportunistic Infections in Medium and Small-Sized Vessel Vasculitis: Based on a Retrospectivestudy on 108 Patients
Raphaele Mestiri¹, Lafarge Antoine², Jean-Jacques Tudesq³, Marc Pineton de Chambrun⁴, Melanie Roriz⁵, Stéphane Bally⁶, Laurent Alric⁷, Damien Sène⁸, Thomas Quémeneur⁹, Cécile-Audrey Durel¹⁰, Brigitte Gilson¹¹, Alice Berezne¹², Anne-Marie Ruppert¹³, Raphaele Seror¹⁴, Philippe Guilpain¹⁵, Xavier Puéchal¹⁶, Luc Mouthon¹⁷, Loïc Guillevin¹⁶ and Benjamin Terrier¹⁸, ¹Internal Medicine, Cochin hospital, Paris, France, ²Medecine Interne, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ³Internal Medicine, CHU Montpellier, Montpellier, France, ⁴Université Pierre et Marie Curie, Paris, France, ⁵Université Paris-Diderot, Paris, France, ⁶Nephrology, CH Chambery, Chambery, France, ⁷Internal Medicine, CHU Toulouse, Toulouse, France, ⁸Lariboisière Hospital, Paris Diderot University, Paris, France, ⁹Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ¹⁰Internal Medicine, Hôpital Edouard Herriot, lyon, France, ¹¹Internal Medicine, CH Verdun, Verdun, France, ¹²Internal Medicine, CH Annecy, Annecy, France, ¹³Pulmonology, Tenon hospital, Paris, France, ¹⁴Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Rheumatology, Université Paris Sud, Le Kremlin Bicetre, France, ¹⁵Montpellier, Montpellier, France, ¹⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁷Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ¹⁸Centre de Référence des Maladies Auto-immunes et Systémiques Rares, Vascularites Nécrosantes et Sclérodermie Systémique, Service de Médecine Interne, Hôpital Cochin, APHP, INSERM U1016, Université Paris Descartes, Paris, France
Background/Purpose: Overall survival has been markedly improved during the last decades in systemic vasculitis. In contrast, the use of immunosuppressive agents led to an increased…
Abstract Number: 18L • 2017 ACR/ARHP Annual Meeting
Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis
Rona Smith¹, Rachel Jones², Ulrich Specks³, Carol A McAlear⁴, Kim Mynard², Simon Bond², David Jayne⁵ and Peter A. Merkel⁶, ¹Department of Medicine, University of Cambridge, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ³Mayo Clinic College of Medicine, Rochester, MN, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

Background/Purpose: RITAZAREM (ClinicalTrials.gov: NCT01697267) is an international, randomized, controlled trial comparing rituximab with azathioprine as maintenance therapy after induction of remission with rituximab and glucocorticoids…
Abstract Number: 1750 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular and Thrombotic Disease Among Patients with Incident ANCA-Associated Vasculitis: A 20 Year Population Based Cohort Study
Alvise Berti^1,2, Eric L. Matteson^3,4, Cynthia S. Crowson^5,6, Ulrich Specks⁷ and Divi Cornec^8,9, ¹Department of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ²Department of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, ³Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Division of Epidemiology, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁷Mayo Clinic College of Medicine, Rochester, MN, ⁸Department of Rheumatology, Brest Teaching Hospital, Brest, France, ⁹Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: ANCA-associated vasculitides (AAV) are characterized by inflammation and necrosis of small-sized vessels. Because cardiovascular disease (CVD) is a leading contributor to morbidity and mortality,…
Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting
Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…
Abstract Number: 1751 • 2017 ACR/ARHP Annual Meeting
Association of a TNFSF4 Upstream Region Single Nucleotide Polymorphism with Susceptibility to Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Yuka Iwahashi¹, Aya Kawasaki¹, Fumio Hirano², Ken-ei Sada³, Daisuke Tsukui⁴, Yuya Kondo⁵, Shigeto Kobayashi⁶, Hidehiro Yamada⁷, Hiroshi Furukawa¹, Kenji Nagasaka⁸, Takahiko Sugihara⁹, Kunihiro Yamagata¹⁰, Takayuki Sumida⁵, Shigeto Tohma¹¹, Hajime Kono⁴, Shoichi Ozaki⁷, Seiichi Matsuo¹², Hiroshi Hashimoto¹³, Hirofumi Makino¹⁴, Yoshihiro Arimura¹⁵, Masayoshi Harigai¹⁶ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ²Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁶Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁷Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁸Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ⁹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁰Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ¹¹Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹²Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹³Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Okayama University Hospital, Okayama, Japan, ¹⁵First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: In the epidemiology of ANCA-associated vasculitis (AAV), an obvious difference between European and Asian populations has been reported. According to the clinical classification, granulomatosis…
Abstract Number: 1778 • 2017 ACR/ARHP Annual Meeting
Prophylactic Treatment and Incidence of Pneumocystis Jirovecci Pneumonia in Japanese Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Izaya Nakaya¹, Ken-ei Sada², Jun Soma¹, Yoshihiro Arimura³, Masayoshi Harigai⁴, Kunihiro Yamagata⁵, Hirofumi Makino⁶ and Seiichi Matsuo⁷, ¹Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ⁴Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁶Okayama University Hospital, Okayama, Japan, ⁷Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Pneumocystis jiroveciipneumonia (PCP) is a fatal complication in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). However, the current situation of prophylactic treatment of PCP and its…
Abstract Number: 1752 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis
Divi Cornec¹, Brian Kabat¹, John Mills¹, Melissa Cheu², Amber Hummel¹, Darrell Schroeder¹, Matthew Cascino³, Paul Brunetta³, David Murray¹, Melissa Snyder¹, Fernando Fervenza¹, Gary S. Hoffman⁴, Cees G.M. Kallenberg⁵, Carol A. Langford⁶, Peter A. Merkel⁷, Paul A. Monach⁸, Philip Seo⁹, Robert F. Spiera¹⁰, E. William St Clair¹¹, John H. Stone¹², David Barnidge¹ and Ulrich Specks¹³, ¹Mayo Clinic, Rochester, MN, ²Genentech Inc., South San Francisco, CA, ³Genentech, Inc., South San Francisco, CA, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, MN, ⁸Boston University School of Medicine, Boston, MA, ⁹Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Rheumatology, Duke University Medical Center, Durham, NC, ¹²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹³Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Response to rituximab (RTX) is variable in patients with ANCA-associated vasculitis (AAV), and predictors of treatment efficacy/relapse risk would be useful. Previous studies have…
Abstract Number: 1844 • 2017 ACR/ARHP Annual Meeting
Circulating Cytokine Profiles Reflect ANCA Specificity in Patients with ANCA-Associated Vasculitis
Alvise Berti¹, Roscoe Warner², Kent Johnson³, Divi Cornec⁴, Darrell Schroder⁵, Brian Kabat⁵, Peter A. Merkel⁶, Carol A. Langford⁷, Gary S. Hoffman⁸, Cees G.M. Kallenberg⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene St. Clair¹², John H. Stone¹³, Ulrich Specks¹⁴ and Paul A. Monach¹⁵, ¹Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ²University of Michigan Medical School, Ann Arbor,, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²Department of Medicine, Duke University Medical Center, Durham, NC, ¹³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁴Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Boston University School of Medicine, Boston, MA
Background/Purpose: To evaluate serum cytokine and chemokine profiles in patients with ANCA-associated vasculitis (AAV) classified by ANCA specificity (proteinase 3 (PR3)-ANCA versus myeloperoxidase (MPO)-ANCA) or…
Abstract Number: 1755 • 2017 ACR/ARHP Annual Meeting
Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis
Hiromichi Tamaki¹, Robert Butler² and Carol A. Langford³, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: Low-dose trimethoprim-sulfamethoxazole (LDTS, 160mg-800mg 3x/week or 80mg-400mg/day) is effective for prevention of Pneumocystis jiroveci pneumonia (PCP), a serious opportunistic infection seen in patients with…
Abstract Number: 1846 • 2017 ACR/ARHP Annual Meeting
Increased CD38hiCD27+ Plasmablast Frequency in Remission Predicts Relapsing Disease in Granulomatosis with Polyangiitis Patients
Anouk von Borstel¹, Wayel H. Abdulahad², Abraham Rutgers², Judith Land², Coen A. Stegeman¹, Peter Heeringa³ and Jan-Stephan F. Sanders¹, ¹Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Patients with granulomatosis with polyangiitis (GPA) are prone to disease relapse. Changes in anti-neutrophil cytoplasmic autoantibodies (ANCA) levels can predict relapses in individual patients…
Abstract Number: 1758 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Infection in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of 126 Wegent Trial Patients
Xavier Puéchal¹, Christian Pagnoux², Elodie Perrodeau³, Mohamed Hamidou⁴, Jean-Jacques Boffa⁵, Xavier Kyndt⁶, François Lifermann⁷, Thomas Papo⁸, Dominique Merrien⁹, Amar Smail¹⁰, Philippe Delaval¹¹, Catherine Hanrotel-Saliou¹², Bernard Imbert¹³, Chahéra Khouatra¹⁴, Marc Lambert¹⁵, Charles Leské¹⁶, Kim H. Ly¹⁷, Edouard Pertuiset¹⁸, Pascal Roblot¹⁹, Marc Ruivard²⁰, Jean-François Subra²¹, Jean-Francois Viallard²², Benjamin Terrier²³, Pascal Cohen²³, Luc Mouthon²⁴, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group²⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Paris Hotel Dieu, Paris, France, ⁴Medecine Interne, CHU Hôtel Dieu, Nantes, France, ⁵Paris Tenon, Paris, France, ⁶Valenciennes, Valenciennes, France, ⁷Dax, Dax, France, ⁸Paris Bichat, Paris, France, ⁹Compiègne, Compiègne, France, ¹⁰Amiens, Amiens, France, ¹¹Rennes, Rennes, France, ¹²Brest, Brest, France, ¹³Grenoble, Grenoble, France, ¹⁴Lyon, Lyon, France, ¹⁵Lille, Lille, France, ¹⁶Cholet, Cholet, France, ¹⁷Limoges, Limoges, France, ¹⁸Pontoise, Pontoise, France, ¹⁹Poitiers, Poitiers, France, ²⁰CHU Estaing, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, ²¹Angers, Angers, France, ²²Bordeaux, Bordeaux, France, ²³Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ²⁴Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, ²⁵Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France
Background/Purpose: Adverse events, rather than active vasculitis, are the greatest threat to patients with ANCA-associated vasculitides (AAVs) during the first year of therapy but long-term…
Abstract Number: 1849 • 2017 ACR/ARHP Annual Meeting
Urinary Epidermal Growth Factor and Monocyte Chemoattractant Protein-1 As Biomarkers of Renal Involvement in ANCA-Associated Vasculitis
Catherine E. Najem¹, Wenjun Ju², Viji Nair², David Cuthbertson³, Rennie L. Rhee¹, Laura Mariani⁴, Simon Carette⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol A. McAlear⁹, Paul A. Monach¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁵, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹, Steven R. Ytterberg¹⁴, Jeffrey Krischer¹⁵, Matthias Kretzler⁴ and Peter A. Merkel¹⁶, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Michigan, Ann Arbor, MI, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Boston University School of Medicine, Boston, MA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵University of South Florida, Tampa, FL, ¹⁶Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose :Epidermal growth factor (EGF) mediates distal tubular epithelial cell function and regeneration. Monocyte chemoattractant protein-1 (MCP-1) participates in recruitment of leukocytes to areas of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].